Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2000-04-05
2008-03-11
Allen, Marianne P. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C530S329000, C514S011400, C514S016700
Reexamination Certificate
active
07342090
ABSTRACT:
The crystal structure of the Fab′ fragment of Mab 2F5, a potent neutralizer of both laboratory strains and primary clinical isolates of most clades of HIV-1, both uncompleted and complexed with the largely conserved peptide sequence ELDKWAS of the viral envelope protein gp41, has been elucidated and the characteristics of peptide-protein interactions determined. Having regard to such determination, the peptide-mimetics are constrained in the three-dimensional structure to provide an increased immunogenicity to the epitope sequence.
REFERENCES:
patent: 5831034 (1998-11-01), Katinger et al.
patent: WO 95/07354 (1995-03-01), None
patent: WO 96/02273 (1996-02-01), None
Muster, T., et al., A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1, J. Virol., 67, 6642-6647 (1993).
Muster, T., et al., Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. virology, 68, 4031-4034 (1994).
Purtscher, M., et al., A broadly neutralizing human monoclonal antibody against pg41 of human immunodeficiency virus type 1 (HIV-1) AIDS Res. And Human Retroviruses, 10, 1651-1658 (1994).
Conley, A.J., et al., Neutralization of divergent human immunodefidiciency virus type 1 varints and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA, 91, 3348-3352(1994).
Trkola, A., et al., Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IGG. J. Virology, 69, 6609-6617 (1995).
Burton D.R., A vaccine for HIV type 1: The antibody perspective. Proc. Natl. Acad. Sci. USA, 94, 10018-10023 (1997).
Ernst W., et al., Baculovirus surface display: Construction and screening of a eukaryotic epitope library, Nucl. Acids Res. 26, 1718-1723 (1998).
Cook, J., et al., Recombinant antibodies with conformationally constrained HIV type 1 epitope inserts elicit glycoprotein 160-specific antibody responses in vivo. AIDS Res. Human Retroviruses, 13, 449-460 (1997).
Chan, D.E. & Kim, P.S., HIV entry and its inhibition, Cell, 93, 681-684 (1998).
Navaza, J., AMoRe—an automated package for molecular replacement, Acta Crystallogr., A50, 157-163 (1994).
Jeffrey, P.D., et al., The X-ray structure of anti-tumour antibody in complex with antigen. Nature Struct. Biol., 2, 466-471 (1995).
Brunger, A.T., et al., Crystallography and NMR system: A new software system for macromolecular structure determination, Acta Cryst. D, 54, 905-921 (1998).
Kraulis, P.J., MOLSCRIPT: a program to produce both detailed and schematic plots of protein structure, J., Applied Cryst., 24, 946-950 (1991).
Merritt, E.A. & Murphy, M.E.P. Raster 3D Version 2.0, A program for photoreolislic Molecular graphics. Acta Cryst. D50, 869-873, (1994).
Jones, T.A. et al., Improved methods for building protein models in electron density maps and the location of errors in these models . . . Acta Cryst. A47, pp. 110-119 (1991).
Evans, S.V., SETOR: hardware-lighted three-dimensional solid model representations of macromolecules, J. Mol. Graph., 11, 134-8, (1993).
Riddles et al., Reassessment of Ellman's Reagent (1983), Methods Enzym. vol. 91pp. 49-60.
Chong et al., Structural and functional analysis of the S1 subunit of pertussis toxin using synthetic peptides. (1991), Mol. Immunol. vol. 28, pp. 239-245.
Mascola, J.R., et al. Potent and synergistic Neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunolobulin combined with monoclonal antibodies 2F5 and 2G12. J. Virology, 71, 7198-7206 (1997).
Eckhart, L., et al., Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigens of hepatitus B. virus. J. of General Virology, 77, 2001-2008 (1996).
Kunert, R., et al., Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonoconventional D segments in the human monoclonal antibodies 2G12 and 2F5, AIDS Res. and Human Retroviruses, 14, 1115-1128, (1998).
Richardson, J.S., The anatomy and taxonomy of protein structure, Adv. Protein Chem., 34, 167-339, (1981).
Gallaher, W.R., et al., A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. And Human Retroviruses, 5, 431-440 (1989).
Weissenhom, W., et al., Atomic structure of the ectodomain from HIV-1 gp41. Nature, 387, 426-430 (1997).
Tan, K., et al., Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA, 94, 12303-12308 (1997).
Chan, D., et al., Core structure of gp41 from the HIV envleope glycoprotein. Cell, 89, 263-273 (1997).
Malashkevich, V.N., et al., Crystal structure of the simian immunodeficiency virus (SI) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides, Proc. Natl. Acad. Sci. USA, 95, 9134-9139 (1998).
Yang, Z.N., et al., High resolution structure of simian immunodeficiency virus gp41 ectodomain, Abstracts, American Crystallographic Association Annual Meeting, 1998.
Caffrey, M., et al., Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41, the EMBO J., 17, 4572-4584 (1998).
Lim L., et al., The three-dimensional structure of Schistosoma japonicum glutathione S-transferase fused with a six-amino acid conserved neutralizing epitope of gp41 from HIV. (1994) 3, 2233-2244.
Chong Pele
Klein Michel H.
Pai Emil F.
Pedyczak Arthur
Allen Marianne P.
Sanofi Pasteur Limited
Sim & McBurney
Stewart Michael I.
University of Toronto
LandOfFree
Fab-epitope complex from the HIV-1 cross-neutralizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fab-epitope complex from the HIV-1 cross-neutralizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fab-epitope complex from the HIV-1 cross-neutralizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977668